Clinical Trial Update: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer [Phase 2, Phase 3]

View source ↗

Summary

An ongoing Phase 2/3 clinical trial evaluating a decitabine-primed carboplatin-paclitaxel regimen for ovarian cancer (FIGO stages II to IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Dacogen (decitabine)
• Paraplatin (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | Phase 2, Phase 3 | Status: UNKNOWN